Table 1.

Clinicopathological characteristics of the study cohort according to KRAS p.G12C mutation

Clinicopathological characteristics	KRAS p.G12C		P value
	Non-mutated (n = 506)	Mutated (n = 6)
Age, mean (SD), yearsa	66.37 (10.99)	59.93 (7.66)	0.328
Sex, n (%) with data
Female	325 (64.23)	5 (83.33)	0.430
Male	181 (35.77)	1 (16.67)
Smoking, n (%) with data
Never smoker	295 (58.30)	4 (66.67)	0.392
Former smoker	174 (34.39)	1 (16.67)
Active smoker	37 (7.31)	1 (16.67)
Histology, n (%) with data
Adenocarcinoma	472 (93.28)	6 (100)	1.000
Adenosquamous	17 (3.36)	0 (0)
Large cell	7 (1.38)	0 (0)
Undifferentiated	9 (1.78)	0 (0)
Other	1 (0.20)	0 (0)
First-line TKI, n (%) with data
Afatinib	81 (16.01)	3 (50)	1.000
Erlotinib	44 (8.70)	1 (16.67)
Gefitinib	62 (12.25)	2 (33.33)
NA	319 (63.04)	0 (0)
Metastases location at stage IV, n (%) with data
Local	94 (18.58)	1 (16.67)	0.621
Bone	59 (11.66)	0 (0)	0.312
CNS	34 (6.72)	1 (16.67)	0.560
Liver	24 (4.74)	1 (16.67)	0.434
NA	320 (63.24)	3 (50)
EGFR mutation, n (%) with data
Common	385 (76.09)	4 (66.67)	0.062
Uncommon	28 (5.53)	2 (33.33)
NA	93 (18.38)	0 (0)
EGFR p.T790M mutation, n (%) with data
Non-mutated	341 (67.39)	6 (100.00)	0.184
Mutated	162 (32.02)	0 (0)
NA	3 (0.59)	0 (0)
Second-line treatment, n (%) with data
First-/second-generation TKI	21 (4.15)	0 (0)	0.007
Antiangiogenic	1 (0.2)	0 (0)
Immunotherapy	2 (0.4)	1 (16.67)
Osimertinib	51 (10.08)	0 (0)
Palliative care	5 (0.99)	0 (0)
Chemotherapy	15 (2.96)	3 (50)
NA	411 (81.23)	2 (33.33)
Progression site, n (%) with data
Local	52 (10.28)	1 (16.67)	0.552
Bone	22 (4.35)	0 (0)	0.563
CNS	16 (3.16)	1 (16.67)	0.497
Liver	12 (2.37)	2 (33.33)	0.071
NA	425 (83.99)	3 (50)

CNS, central nervous system; EGFR, epidermal growth factor receptor; NA, not available; SD, standard deviation; TKI, tyrosine kinase inhibitor.

^aThree hundred and twenty patients without information (all belong to the non-mutated group).